Nanomedicine News

RSS

Nanomix Commences Evaluation of Omega-3 Cardiac Panel

Nanomix Inc., a leading nanotechnology company focused on development of next generation point of care diagnostic tests to enable earlier and more accurate testing in hospital and pre-hospital settings, announced today that it has initiated clinical testing in the U.S. to evaluate the Omega-3 Cardiac Panel.

From Nanomix Inc 12 Feb 2013

Researchers Work on Developing New HIV Vaccines

With the recent launch of MIT’s Institute for Medical Engineering and Science, MIT News examines research with the potential to reshape medicine and health care through new scientific knowledge, novel treatments and products, better management of medical data, and improvements in health-care delivery.

11 Feb 2013

ASU-Mayo Clinic Research Team Wins Grant to Develop Nanobodies Targeting Amyloid-â Oligomers

An external panel of venture capitalists, entrepreneurs and medical device manufacturers has awarded $100,000 grants to two joint Arizona State University-Mayo Clinic research teams that are working to apply personalized medicine to the treatment of Alzheimer’s disease and cerebral aneurysms.

11 Feb 2013

Degradable Nanoscale Shell Carries Proteins to Cancer Cells

Scientists create nanoscale vehicle to battle cancer without harming healthy cells

7 Feb 2013

Red Blood Cells Trap Drug-Carrying Nanoparticles

Many medically minded researchers are in hot pursuit of designs that will allow drug-carrying nanoparticles to navigate tissues and the interiors of cells, but University of Michigan engineers have discovered that these particles have another hurdle to overcome: escaping the bloodstream.

6 Feb 2013

Celsion Updates Status of its Patent Application ‘Method of Storing Nanoparticle Formulations’

Celsion Corporation today announced that Zheijang HISUN Pharmaceutical Company (HISUN) does not plan to pursue the exclusive option to license ThermoDox® for the Greater China market. Accordingly, the parties will not enter into the exclusive license agreement, and Celsion will not receive nor will it require any future payment for the option or license, as contemplated in the Exclusive Option Agreement announced on January 22, 2013.

6 Feb 2013

Nanodermatology Society Proclaims 2013 as the Year of Topical Delivery

For over a century, each year has been marked by extraordinary progress in both medicine and biotechnology. Just one hundred years ago, Nicholay Anichkov made the earliest link between cholesterol and atherosclerosis, an...

6 Feb 2013

Alnylam Licenses PCS Cholesterol Program with Lipid Nanoparticle Delivery Technology to Medicines Company

As we told our readers last week, industry observers and Wall Street Analysts both feel that the RNAi space will heat up significantly in 2013. To that point, both Alnylam Pharmaceuticals, Inc and Tekmira Pharmaceuticals Corporation started February off with news.

5 Feb 2013

Tekmira Lipid Nanoparticle Delivery Technology Phase 1 Study to be Presented at AACR

Tekmira Pharmaceuticals Corporation, a leading developer of RNA interference (RNAi) therapeutics, announced today that it has been selected as an oral presenter at the annual meeting of the American Association for Cancer Research (AACR) taking place in Washington, DC from April 6-10, 2013.

5 Feb 2013

Pharmsyntez to Distribute Oasmia’s Nanoparticle Anti-Cancer Formulation in Russia and CIS Countries

Pharmsyntez obtains exclusive marketing and distribution rights in Russia and the countries encompassed by the Commonwealth of Independent States (CIS), and the agreement includes profit sharing on net sales in the region between the two companies.

5 Feb 2013